Parvin Asset Management’s ImmunityBio IBRX Stock Holding History

Parvin Asset Management’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$350K	Hold	40,000	–	–	0.27%	96
2026 Q1	$307K	Buy	+40,000	New	+$274K	0.22%	106

Other funds holding IBRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Parvin Asset Management's IBRX Position: Q2 2026 in Review

Parvin Asset Management held its ImmunityBio (IBRX) position steady in Q2 2026 at 40,000 shares worth $350K. The position accounts for 0.27% of the portfolio, ranked #96.

Parvin Asset Management first reported a position in IBRX in Q1 2026 and has held it in 2 quarters since. 405 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

Parvin Asset Management held 40,000 shares of ImmunityBio worth $350K as of Q2 2026.
Parvin Asset Management left its ImmunityBio share count unchanged in Q2 2026.
ImmunityBio made up 0.27% of Parvin Asset Management's portfolio in Q2 2026, its #96 holding.
Parvin Asset Management first reported a position in ImmunityBio in Q1 2026 and has held it in 2 quarters since.
405 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Parvin Asset Management's 13F filing for Q2 2026, filed 17 Aug 2026.